Blue Lake Biotechnology, Inc., a clinical-stage biotechnology company, announced the enrollment of the first participant in a phase 1 clinical trial of their intranasal BLB-201 vaccine for RSV (respiratory syncytial virus) in Charleston, South Carolina. BLB-201 is based on an attenuated strain of PIV5 that expresses the F protein of RSV.
In preclinical studies, BLB-201, delivered intranasally as a single dose, induces serum antibody and mucosal antibody responses as well as cell-mediated immune responses, and is protective against RSV challenge infection in various animal models. Delivered through the nose without injections, Blue Lake
